Phase 3 data show the Pfizer/BioNTech vaccine is effective at preventing COVID-19 6 months after the second dose; the USDA will not move forward with a plan to cut food stamps; data reveal spike in drug overdose deaths during pandemic.
New phase 3 trial data from Pfizer/BioNTech indicate the companies’ vaccine is effective 6 months after individuals received their second dose with no serious safety concerns reported, according to NBC News. The data also show the vaccine is effective against B.1.351, a COVID-19 variant that first emerged in South Africa. The CEO and cofounder of BioNTech said the results indicating the vaccine’s efficacy against the variant mark a critical step forward in reaching herd immunity. The results also allow the companies to submit a full Biologics License Application to the FDA. Currently, the vaccine is being distributed under an Emergency Use Authorization.
A plan proposed by former President Donald Trump to cut federal food assistance benefits to around 700,000 adults has been dropped by the US Department of Agriculture (USDA), CBS News reports. The plan, which would have cut food stamps by implementing tightened work requirements for working-age adults without children, was rejected by the Biden administration and condemned by anti-hunger advocates. The Trump administration had formerly appealed a federal court ruling that blocked the restrictions on the Supplemental Nutrition Assistance Program (SNAP). As of November, approximately 41.4 million people are enrolled in SNAP—an increase of 13% from February 2020, prior to the COVID-19 pandemic.
Drug overdose deaths increased by 26.8% during the COVID-19 pandemic, accounting for 88,000 lives lost in a 12-month period, the acting director of the White House Office of National Drug Control Policy said. Reported by Axios, illicitly manufactured fentanyl and synthetic opioids were the primary drivers of the increase, which is almost 20,000 more deaths than those reported in 2019 (70,630 deaths). Rates in drug overdoses have been on the rise since 1999 while opioids remain the main cause of drug overdose fatalities. In response to the data, the Biden administration released a plan to address the crisis which involves removing barriers preventing the persecution of buprenorphine.
A Look at the Legal and Legislative Landscape Impacting Drug Costs for Patients
October 23rd 2024Kimberly Westrich, MA, of National Pharmaceutical Council, and Adam Colborn, JD, of AMCP, run through the current status of lawsuits and lawmaking at the federal and state levels related to pharmacy benefit managers and cost-shifting programs.
Read More
Healing Wounds Through Peer Support
September 16th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In this third episode, we speak with Kim MacDonald-Wilson, ScD, CPRP, and Tracy Carney, CPS, CPRP.
Listen
Racial/Ethnic Disparities in Cost-Related Barriers to Care Among Near-Poor Beneficiaries
October 23rd 2024Among near-poor Black and Hispanic individuals, Medicare Advantage was associated with increased vision care and some, although not uniform, reductions in access disparities vs traditional Medicare.
Read More
Combatting the Opioid Epidemic: Insights From the Front Lines
September 2nd 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In this first episode, we speak with Michael Lynch, MD, associate professor of emergency medicine at the University of Pittsburgh and an attending emergency physician and medical toxicologist at the University of Pittsburgh Medical Center.
Listen
Vaccine Hesitancy: COVID-19 to Influenza
October 22nd 2024Vaccine hesitancy grew more prominently in the wake of COVID-19 and the spread of misinformation. This flu season, seeking out reliable sources of health information will help individuals make the best decisions to protect themselves.
Read More